Hypoglycemic activity and mechanisms of myricetin

Nat Prod Res. 2022 Dec;36(23):6177-6180. doi: 10.1080/14786419.2022.2058941. Epub 2022 Apr 4.

Abstract

Myricetin has been reported to have a wide variety of beneficial physiological functions. The present study was designed to investigate the mechanism of high purity myricetin, as a hypoglycemic functional component on high fat diet (HFD) fed streptozotocin (STZ) induced diabetic rats. Four-week antihyperglycemic effects of myricetin were assayed. The results showed that continuous administration of myricetin (50 and 200 mg/kg body weight) in HFD/STZ induced diabetic rats dose-dependently reduced the body serum glucose and insulin. Furthermore, administrations of myricetin significantly increased the expression of insulin receptor (InsR) and glucose transporter 4 (GLUT4) gene and increased the expression of glucose-6-phosphatase (G-6-Pase) and phosphoenolpyruvate carboxykinase (PEPCK) gene. Moreover, myricetin protected pancreatic tissue from HFD fed STZ induced apoptosis through regulation of Bcl-2 associated X (Bax) gene and B-cell lymphoma-2 (Bcl-2) gene. The experimental results show that myricetin has significant health benefits and can be explored as a potentially promising dietary supplement for auxiliary hypoglycemic.

Keywords: G6Pase; GLUT4; Hypoglycemic; apoptosis; myricetin.

MeSH terms

  • Animals
  • Blood Glucose
  • Diabetes Mellitus, Experimental* / chemically induced
  • Diabetes Mellitus, Experimental* / drug therapy
  • Hypoglycemic Agents* / metabolism
  • Hypoglycemic Agents* / pharmacology
  • Insulin / metabolism
  • Insulin / pharmacology
  • Liver
  • Proto-Oncogene Proteins c-bcl-2 / metabolism
  • Rats
  • Streptozocin / pharmacology

Substances

  • Hypoglycemic Agents
  • myricetin
  • Blood Glucose
  • Insulin
  • Streptozocin
  • Proto-Oncogene Proteins c-bcl-2